KLRC2 and leukemia: Interestingly, leukaemia and lymphoma patients, undergoing hematopoietic cell transplantation had a reduced relapse-risk when experiencing HCMV reactivations, and it was hypothesized that NKG2C+ NK cells expanding in response to HCMV may contribute to protection against relapses (27, 28).